Effect of flouxetine versus citalopram on sexual dysfunction, serum oxytocin and prolactin levels in wome

Phase 4

Completed

• Conditions: Sexual dysfunction; Depression; Reproductive Health and Childbirth - Other reproductive health and childbirth disorders; Mental Health - Depression

• Registration Number: ACTRN12614000869673
• Lead Sponsor: Mohammad Abbasinazari

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-08-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

All women need to be experiencing symptoms of sexual dysfunction with diagnosis of depression between 18-45 years old in the psychosomatic clinic of Taleghani hospital(Tehran, Iran) with informed consent

Exclusion Criteria

patients with renal failure or hepatic failure, pregnat or breast feeding women

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
sing Female Sexual Function Index(FSFI) questionairre for assesment of sexual dysfunction[After 4 weeks of treatment either with flouxetine or citalopram]

Secondary Outcome Measures

Name	Time	Method
assesment of oxytocin in serum of studied patients[After 4 weeks of treatment with either flouxetine or citalopram];Assessment of prolactin in serum of studied patient[After 4 weeks of treatment with either fluoxetine or citalopram ]